Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 23, 2024MoleculesOpen Access

In Silico Comparison of Bioactive Compounds Characterized from Azadirachta indica with an FDA-Approved Drug against Schistosomal Agents: New Insight into Schistosomiasis Treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

BOBabatunji Emmanuel OyinloyeDSDavid ShamakiEAEmmanuel Ayodeji Agbebi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Oyinloye et al. (2024) studied this question.

synapsesocial.com/papers/68e6df83b6db64358765abb7https://doi.org/10.3390/molecules29091909
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Computer-aided discovery of novel SmDHODH inhibitors for schistosomiasis therapy: Ligand-based drug design, molecular docking, molecular dynamic simulations, drug-likeness, and ADMET studies2024 · 7 citations
  2. 2Unveiling potent inhibitors for schistosomiasis through ligand-based drug design, molecular docking, molecular dynamics simulations and pharmacokinetics predictions2024 · 25 citations
  3. 3Computational design of novel therapeutics targeting Schistosomiasis, a neglected tropical disease2024 · 2 citations
  4. 4In-silico exploration and structure-based design of Praziquantel derivatives as potential inhibitors of schistosoma mansoni Glutathione S-transferase (SmGST)2024 · 6 citations
  5. 5Qualitative And Quantitative Profiling Of Azadirachta Indica Against Bulinus Globosus Infective Stage: Implication For Control2025